Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

NYSE:PFE - Post Discussion

Pfizer Inc > Pfizer/BioNTech COVID-19 vaccine cleared by EU
View:
Post by Humanist on Dec 21, 2020 8:46pm

Pfizer/BioNTech COVID-19 vaccine cleared by EU

Pfizer/BioNTech COVID-19 vaccine cleared by EU

Dec. 21, 2020 1:01 PM ET/////Pfizer Inc. (PFE)By: Dulan Lokuwithana

The European Commission greenlighted the COVID-19 vaccine candidate from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), hours after the European Medicines Agency issued a positive opinion to recommend it for conditional marketing authorization.

  • The decision by the EU’s executive arm will allow the two companies to roll out the vaccine across the 27-nation bloc. The deliveries are expected to start on Saturday, with inoculations beginning across the EU between December 27-29.
  •  
  • After receiving the positive opinion from EMA, the CEO of Pfizer’s German partner, BioNTech, said, “Being in the heart of the EU, we are thrilled to be one step closer to potentially delivering the first vaccine in Europe to help combat this devastating pandemic.”
  •  
  • The decision by the Committee for Medicinal Products for Human Use of EMA was based on Phase 3 clinical data published in The New England Journal of Medicine in early December.
 
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities